Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neoleukin Therapeutics, Inc.

http://www.neoleukin.com

Latest From Neoleukin Therapeutics, Inc.

Finance Watch: Acrivon Adjusts Expectations To Launch $99.4m IPO

Public Company Edition: Acrivon launched the 20th biopharma IPO in the US for 2022. Also, Q3 updates reveal job cuts at Tricida, Harpoon, Neoleukin and more; APIM Therapeutics will reverse merge with Nordic Nanovector; plus other follow-on offerings, royalty deals and a sale-leaseback. 

Financing Business Strategies

Database In Works To Help Drugmakers Avoid Molecules That Trigger Immune Reactions

Individuals from pharma, biotech, technology and academia create shared database to facilitate development of therapeutic proteins that are unlikely to provoke immune reactions.

Biologics Research & Development

Scrip Asks…What Does 2021 Hold For Biopharma? Part 5: Business Environment And Strategy

A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.

Artificial Intelligence Brexit
See All

Company Information

UsernamePublicRestriction

Register